Featured Bioprocessing Editorial

1. Are You Still Evaluating CMOs When You Really Need A CDMO? 10/29/2025

   Outsourcing adds capacity and specialized knowledge to your supply chain. But contractors come in several types. Here's how to pick the right one.

2. Here's A Thought: What If Gene Editing Didn't Use Bacterial Enzymes? 10/27/2025

   Citing the dismally few wins for CRISPR/Cas9 and other gene editing systems, one scientist proposes delivering zinc finger DNA-binding peptides using AAV6 vectors.

3. Dual Membrane Preconditioning Can Improve Concentration, Cut HCPs 10/27/2025

   Research from Penn State, the FDA, and Takeda shows how combination filtration and purification steps improve output and reduce impurities.

4. Analyzing CAR-T Surface Proteins With Immunoprecipitation Coupled With Mass Spectrometry 10/24/2025

   Among other benefits, the approach can help compare CAR constructs, evaluate the effects of manufacturing processes, and monitor changes in protein interactions.

5. Program Manager Alignment And Integration: Best Practices When Working With A CDMO 10/23/2025

   This Q&A discusses best practices for integrating program managers into a sponsor company and how program managers help bridge the gaps between various stakeholders.

6. New Guide Aims To Build Robust Framework For Digital Validation Tools 10/22/2025

   The ISPE's new guide addresses software for managing digital assets related to qualification, verification, validation, and compliance assurance.

7. Pfizer's Accord For A Healthier World Program Challenges Stability Study Norms 10/22/2025

   The company developed a novel approach to address the historic lack of stability testing for underserved parts of the world, near the equator.

8. How Sethera Harnesses A Promiscuous Enzyme To Make Recombinant Peptides 10/21/2025

   A class of enzymes previously believed to be specific and intolerant of change might actually have broad applicability.

9. Takeda Reimagines Biopharma Quality For The Digital Age 10/21/2025

   Artificial intelligence, even in its current form, is especially good at synthesizing large data sets. Here's how one company makes the most of it.

10. 100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing 10/17/2025

    Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.